Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.
What Dishman files
- Others56
- Investor Meet24
- Board Meeting17
- Important14
- Updates12
- PPTs10
Dishman Carbogen Amcis subsidiary commissioned a 1,200 kWp ground-mounted solar system at its Swiss site. This significant operational upgrade boosts on-site renewable energy, cuts CO2 emissions, and reinforces the company's long-term sustainability commitment.
Dishman Carbogen Amcis' subsidiary, CARBOGEN AMCIS Shanghai, successfully passed an unannounced GMP inspection by China's NMPA with zero observations. This confirms robust quality standards, crucial for continued operations and global growth.
Company secured consent from its Debenture Trustee to waive three key financial covenants for its ₹50 Cr Non-Convertible Debentures for the fiscal year ended March 31, 2026. This waiver offers the company increased financial flexibility regarding its debt obligations.
Dishman Carbogen Amcis's subsidiary, CARBOGEN AMCIS B.V., secured a GMP Compliance Certificate for its Netherlands Veenendaal site. This confirms high operational quality, crucial for pharmaceutical manufacturing and market access.
Dishman Carbogen Amcis Q3 consolidated net revenue rose 5.5% to ₹719.8 Cr, driven by CDMO. Q3 EBITDA fell to ₹113.1 Cr (15.7% margin) due to lower late Phase III molecules. 9M revenue grew 4.3% to ₹2080.5 Cr, with 9M EBITDA up at ₹402.7 Cr (19.4% margin).